


**Product Name** : Bosutinib  
**Cat. No.** : PC-24042  
**CAS No.** : 380843-75-4  
**Molecular Formula** : C<sub>26</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 530.45  
**Target** : Src  
**Solubility** : 10 mM in DMSO



## Biological Activity

Bosutinib (SKI-606) is a potent, dual Src/Abl inhibitor with IC<sub>50</sub> of 1.2 nM (Src enzyme), inhibits Src autophosphorylation with an IC<sub>50</sub> of 0.25 μM in HT29 cells, inhibits bacterially expressed Abl kinase activity with IC<sub>50</sub> of 1 nM.

Bosutinib (SKI-606) inhibits the growth of the Abl-MLV-transformed fibroblasts with IC<sub>50</sub> of 90 nM

Bosutinib (SKI-606) inhibits v-Abl phosphorylation with IC<sub>50</sub> of 25-50 nM, inhibits STAT5 Phosphorylation.

Bosutinib (SKI-606) inhibits anchorage-independent growth of Src-transformed fibroblasts with an IC<sub>50</sub> of 100 nM, and inhibits Src-dependent protein tyrosine phosphorylation.

Bosutinib (SKI-606) inhibits proliferation in CML cells, inhibits tyrosine phosphorylation of cellular proteins and Bcr-Abl in CML cells.

Bosutinib (SKI-606) displays excellent antitumor activity in Src-transformed fibroblast xenografts in nude mice.

## References

Golas JM, et al. Cancer Res. 2003 Jan 15;63(2):375-81.

Golas JM, et al. Cancer Res. 2005 Jun 15;65(12):5358-64.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com